Archive for the ‘PDE5 selective inhibitors’ Category
What is Levitra?
Today men face more stress and more physical issues then every before. That’s the bad news, the good news is that they are also seeking medical help more often and because of this the medical community can now address some of the medical issues that are surfacing.
One of those medical issues is penile dysfunction. There are now several drugs on the market that can help to alleviate this problem, Levitra is one such medicine. Read the rest of this entry »
Serious cycling can result in serious ED
Adjustments to blood flow, rider angle, seat style can prevent long-term damage
Serious male cycling enthusiasts might want to consider taking a phosphodiesterase type5 inhibitor prior to a long ride to prevent pressure-induced hypo-oxygenation of the penis, according to German researchers.
Penile oxygenation decreased by as much as 97% during cycling, a decline that was significantly reduced when men took sildenafil citrate (Viagra), 50 mg, an hour before cycling. The type of bicycle seat used and the rider’s position during cycling also affected oxygenation to the penis.
ED agent improves sexual pleasure in both partners
Treatment with PDE-5 inhibitor shows improvements in several satisfaction domains
The phosphodiesterase type-5 inhibitor vardenafil (Levitra) significantly improves sexual pleasure and treatment satisfaction in both men with erectile dysfunction and their partners. according to study results presented at the European Association of Urology annual congress here.
More than one-half of all men older than age 40 years are estimated to have some degree of ED. Yet, only 10% of the approximately 30 million men affected in the United States seek treatment for the condition. For the majority of those who do, PDE-5 inhibitors—sildenafil citrate (Viagra), tadalafil (Cialis), and vardenafil—are recognized as first-line therapy for ED management.
“In this report, the rote and impact of the partner is highlighted and clearly shows that effective treatment of male erectile dysfunction yields measurable improvements in partner sexual satisfaction,” said study co-author Gerald Brock, MD, associate professor of urology at St. Joseph’s Medical Center, Lawson Research Institute, London, Ontario, Canada. “While often ignored, ultimately successful erectile dysfunction treatment satisfaction of the male requires that the partner obtains an enhanced experience as well.”
Tadalafil improves symptoms associated with BPH
Findings from a multicenter, randomized, double-blind, placebo-controlled study are consistent with previously reported data showing that tadalafil (Cialis) improves lower urinary tract symptoms associated with BPH. However, the benefit cannot be explained by effects on pressure-flow urodynamics, researchers reported at the European Association of Urology annual congress.
The prospective study randomized 200 men to treatment with tadalafil, 20 mg, or placebo once daily for 12 weeks. At baseline and study completion, patients underwent urodynamics studies and completed International Prostate Symptom Score (IPSS) questionnaires.